HALO
Price
$67.28
Change
+$1.74 (+2.65%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
7.67B
87 days until earnings call
KZIA
Price
$7.90
Change
-$0.37 (-4.47%)
Updated
Aug 15, 04:52 PM (EDT)
Capitalization
9.24M
Interact to see
Advertisement

HALO vs KZIA

Header iconHALO vs KZIA Comparison
Open Charts HALO vs KZIABanner chart's image
Halozyme Therapeutics
Price$67.28
Change+$1.74 (+2.65%)
Volume$20.59K
Capitalization7.67B
Kazia Therapeutics
Price$7.90
Change-$0.37 (-4.47%)
Volume$100
Capitalization9.24M
HALO vs KZIA Comparison Chart in %
Loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KZIA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HALO vs. KZIA commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Hold and KZIA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (HALO: $65.54 vs. KZIA: $8.27)
Brand notoriety: HALO and KZIA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 73% vs. KZIA: 0%
Market capitalization -- HALO: $7.67B vs. KZIA: $9.24M
HALO [@Biotechnology] is valued at $7.67B. KZIA’s [@Biotechnology] market capitalization is $9.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.07B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 1 FA rating(s) are green whileKZIA’s FA Score has 0 green FA rating(s).

  • HALO’s FA Score: 1 green, 4 red.
  • KZIA’s FA Score: 0 green, 5 red.
According to our system of comparison, HALO is a better buy in the long-term than KZIA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 4 TA indicator(s) are bullish while KZIA’s TA Score has 4 bullish TA indicator(s).

  • HALO’s TA Score: 4 bullish, 4 bearish.
  • KZIA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, HALO is a better buy in the short-term than KZIA.

Price Growth

HALO (@Biotechnology) experienced а +5.54% price change this week, while KZIA (@Biotechnology) price change was +0.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.95%. For the same industry, the average monthly price growth was +21.44%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

HALO is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+5.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($7.67B) has a higher market cap than KZIA($9.25M). HALO YTD gains are higher at: 37.084 vs. KZIA (-6.554). HALO has higher annual earnings (EBITDA): 705M vs. KZIA (-26.77M). HALO has higher revenues than KZIA: HALO (1.08B) vs KZIA (2.31M).
HALOKZIAHALO / KZIA
Capitalization7.67B9.25M82,920%
EBITDA705M-26.77M-2,634%
Gain YTD37.084-6.554-566%
P/E Ratio15.00N/A-
Revenue1.08B2.31M46,967%
Total Cash748MN/A-
Total Debt1.51BN/A-
FUNDAMENTALS RATINGS
HALO vs KZIA: Fundamental Ratings
HALO
KZIA
OUTLOOK RATING
1..100
2383
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
36100
SMR RATING
1..100
12100
PRICE GROWTH RATING
1..100
4238
P/E GROWTH RATING
1..100
87100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KZIA's Valuation (45) in the Biotechnology industry is somewhat better than the same rating for HALO (79). This means that KZIA’s stock grew somewhat faster than HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (36) in the Biotechnology industry is somewhat better than the same rating for KZIA (100). This means that HALO’s stock grew somewhat faster than KZIA’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for KZIA (100). This means that HALO’s stock grew significantly faster than KZIA’s over the last 12 months.

KZIA's Price Growth Rating (38) in the Biotechnology industry is in the same range as HALO (42). This means that KZIA’s stock grew similarly to HALO’s over the last 12 months.

HALO's P/E Growth Rating (87) in the Biotechnology industry is in the same range as KZIA (100). This means that HALO’s stock grew similarly to KZIA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOKZIA
RSI
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 15 days ago
68%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KZIA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BMRA3.510.48
+15.84%
Biomerica
VIV12.300.13
+1.07%
Telefonica Brasil SA
GAUZ6.140.04
+0.66%
Gauzy Ltd
RARE29.010.04
+0.14%
Ultragenyx Pharmaceutical
NEXN9.33-0.57
-5.76%
Nexxen International Ltd